Drug Profile
Research programme: antisense oligonucleotides - Stoke Therapeutics
Alternative Names: TANGO ASOLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Stoke Therapeutics
- Class Antiepileptic drugs; Antisense oligonucleotides; Eye disorder therapies; Hepatoprotectants; Neuroprotectants
- Mechanism of Action Methyl-CpG-binding protein 2 expression stimulants; NAV1.1 voltage-gated sodium channel modulators; RNA interference; SYNGAP1 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rett syndrome
- No development reported Dravet syndrome; Haematological disorders; Liver disorders; Neurological disorders; Optic atrophy
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Dravet-syndrome in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 28 Feb 2023 Stoke Therapeutics delivers a notice of termination to Cold Spring Harbor Laboratory for the CSHL Agreement